Analysis of telisotuzumab-EMRELIS medical insurance reimbursement ratio and policy differences in different regions

Telisotuzumab-EMRELIS is a targeted therapy for MET protein-positive non-small cell lung cancer. Since the drug is not currently on the market in China, it is not directly available to patients in China, and it is not included in the national medical insurance reimbursement system. Therefore, neither urban or rural medical insurance nor commercial insurance can cover its cost, and patients must rely on overseas channels or clinical trials to use it.

In overseas markets, terituzumab has been approved for marketing, and the common price is about RMB 45,000 per course of treatment. Since there are no generic drugs yet, the price is relatively high, which imposes a greater financial burden on patients. Therefore, even abroad, patients need to understand drug costs and medical insurance policies in advance in order to plan treatment plans.

There are obvious differences in medical insurance policies in different regions. For example, some commercial insurances in the United States can provide partial reimbursement support to eligible MET positive patients. However, there are differences in reimbursement ratios and access standards among European countries, and some countries require special approval procedures to reimburse drug costs. Such regional differences require patients to fully evaluate local policies and personal economic conditions when choosing medication channels and payment methods.

In terms of clinical recommendations, terituzumab, as a targeted drug, should be used in patients with confirmed MET protein positivity to ensure efficacy and safety. Patients must complete genetic testing before planning to use it and undergo treatment under the guidance of a professional doctor. In addition, since it is not yet available on the market in China, if patients consider purchasing drugs through overseas channels, they should ensure that the source of the drugs is formal and legal, and pay attention to transportation and storage conditions to ensure drug quality and efficacy.

Keyword tag:

ADCdrugs,METtargeted, non-small cell lung cancer, targeted therapy, side effect management, contraindications, regular drug purchase channels, drug prices

Reference:https://en.wikipedia.org/wiki/Telisotuzumab_vedotin